ArticleScientific reports2026
Pomolic acid alleviates CCl
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Liver fibrosis is a wound healing process in response to various chronic liver injuries characterized by the replacement of normal liver by collagen fibers formed from extracellular matrix (ECM), resulting in scarring of the organ. Liver macrophages, a highly heterogeneous and plastic immune cell population, are pivotal in human health and disease, widely involved in the advancement and reversal of liver fibrosis. Interleukin-4 (IL-4) and/or interleukin-13 (IL-13)-induced pro-fibrotic macrophage polarization play a crucial role in promoting liver fibrosis through the secretion of transforming growth factor-β (TGF-β), a key profibrotic cytokine. This study aimed to explore the therapeutic potential and underlying mechanism of pomolic acid (PA) in mitigating carbon tetrachloride (CCl4)-induced liver fibrosis. The results indicated that PA effectively hindered pro-fibrotic macrophage polarization and the release of TGF-β, thereby ameliorating the fibrotic progression. Mechanistically, PA disrupted β-arrestin 2-IRG1 interaction, consequently impeding the ubiquitination-related degradation of IRG1, and ultimately suppressed fatty acid oxidation (FAO)-mediated pro-fibrotic macrophage polarization. Furthermore, PA also demonstrated excellent efficacy in combating oral submucosal fibrosis (OSF). In conclusion, our study confirmed that PA inhibited the advancement of fibrosis by repressing β-arrestin 2-induced pro-fibrotic macrophage polarization. These findings suggest that PA could serve as a promising and broad-spectrum anti-fibrotic drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.